Janux Therapeutics(NASDAQ) JANX

Janux Therapeutics creates medicines that help the body's own immune system kill cancer cells. The company builds smart therapies designed to attack tumors without hurting healthy tissue. These treatments focus on difficult cancers and diseases where the immune system causes harm.

Cancer-Fighting Tools and Technology

• JANX007: Clinical-stage therapy for prostate cancer targeting a specific protein called PSMA.
• JANX011: Treatment for autoimmune diseases designed to clear out harmful cells while improving safety.
• JANX014: Double-masked medicine for prostate cancer that entered clinical testing in April 2026.
• TRACTr and TRACIr Platforms: Technology used to create therapies that guide immune cells to tumors.

Building Partnerships and Pipelines

• Signed a deal with Bristol-Myers Squibb in Jan. 2026 to develop a new tumor-activated therapy.
• Earned a $35.0 million milestone payment from Bristol-Myers Squibb in March 2026.
• Collaborated with Merck in Dec. 2020 to develop next-generation immune therapies for cancer.
• Launched a Phase 1 study for the JANX011 program in Feb. 2026 to treat autoimmune diseases.

Precision in Targeted Therapy

The company uses its TRACTr technology to overcome side effects like cytokine release syndrome, which is an overactive immune response. By masking its medicines, Janux aims to keep the treatments inactive until they reach the tumor site.

A Look at the Numbers

• Collaboration revenue was $14.0 million for the six months ended June 30, 2026.
• Net loss was $46.3 million for the six months ended June 30, 2026.
• The company held $971.7 million in cash and short-term investments as of June 30, 2026.
• Research and development expenses reached $57.8 million for the six months ended June 30, 2026.
• Accumulated deficit was $397.7 million as of June 30, 2026.

The Path Forward

Janux has transitioned from a research-focused firm to a clinical-stage company with multiple drug candidates in human testing. Its expansion into autoimmune treatments alongside oncology highlights a broadening scientific scope.